Nexletol Market Report 2026

The nexletol market size has grown rapidly in recent years. It will grow from $3.21 billion in 2025 to $3.65 billion in 2026 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to limited cholesterol-lowering drug options, high prevalence of hyperlipidemia, reliance on statin therapies, growing hospital and clinic prescriptions, increasing awareness of cardiovascular risks.

The nexletol market size is expected to see rapid growth in the next few years. It will grow to $6.07 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to introduction of bempedoic acid-based therapies, expansion of homecare and long-term care medication delivery, rising cardiovascular disease incidence, growing focus on combination therapies, increasing healthcare infrastructure in emerging markets. Major trends in the forecast period include rising adoption of ldl-c lowering therapies, increasing use of oral administration over injectable forms, expansion of cardiovascular disease awareness programs, growth in prescription-based and otc availability, integration of homecare and long-term care settings for medication use.

The rising incidence of cardiovascular diseases is anticipated to drive the growth of the Nexletol market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The prevalence of cardiovascular diseases is increasing due to more sedentary lifestyles, as insufficient physical activity contributes to weight gain, metabolic disorders, and elevated blood pressure, all of which substantially increase the risk of heart disease. Nexletol supports cardiovascular disease management by lowering low-density lipoprotein (LDL) cholesterol levels, thereby reducing plaque accumulation in the arteries and decreasing the likelihood of heart attacks and other cardiovascular events. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, reflecting a 4% increase from 224.4 per 100,000 in 2023. Therefore, the growing burden of cardiovascular diseases is boosting the growth of the Nexletol market.

Major companies operating in the Nexletol market are increasingly emphasizing the development of innovative oral non-statin LDL-cholesterol-lowering therapies, such as bempedoic acid-based agents, to meet rising demand driven by the limitations associated with statin treatments. Bempedoic acid-based agents are oral lipid-lowering medications that inhibit ATP citrate lyase (ACL), a key enzyme involved in hepatic cholesterol synthesis, thereby reducing LDL cholesterol levels. These agents benefit patients, particularly those who are unable to tolerate statins, by lowering LDL-C through a liver-specific mechanism that minimizes the muscle-related side effects commonly linked to traditional statin therapy. For example, in March 2024, Esperion Therapeutics, Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration for an expanded label covering its products Nexletol (bempedoic acid) and Nexlizet (bempedoic acid plus ezetimibe). This expansion allows their use for LDL-C reduction and cardiovascular risk management in both primary and secondary prevention settings, irrespective of statin use. Nexletol is a once-daily oral formulation containing bempedoic acid that lowers LDL-C and inflammation by inhibiting ACL, has demonstrated reductions in major cardiovascular events in the CLEAR Outcomes trial, and provides a differentiated non-statin oral therapy with a favorable safety profile. The broadened label significantly expands patient eligibility in the US, supporting increased market adoption.

In May 2025, HLS Therapeutics, a Canada-based pharmaceutical company, entered into a partnership with Esperion Therapeutics to commercialize Nexletol. Through this collaboration, HLS Therapeutics seeks to broaden the availability of Nexletol and Nexlizet in Canada, offering additional treatment options for patients with elevated LDL-C levels, particularly those who are statin-intolerant or unable to achieve LDL-C targets with existing therapies. Esperion Therapeutics is a US-based company engaged in the development of Nexletol.

Major companies operating in the nexletol market are Esperion Therapeutics Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati S.p.A., Almirall S.A., Menarini Group, Les Laboratoires Servier, Torrent Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Hetero Drugs Limited, Alkem Laboratories Limited, Wockhardt Limited, Mylan (Viatris Inc.), Teva Pharmaceutical Industries Limited, Apotex Inc., Hikma Pharmaceuticals PLC, Krka d.d., STADA Arzneimittel AG, Sandoz International GmbH.

North America was the largest region in the nexletol market in 2025. The regions covered in the nexletol market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nexletol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the Nexletol market by increasing costs for imported raw materials and active pharmaceutical ingredients (APIs), leading to higher production expenses. Segments such as prescription-based 180 mg tablets and other dosage forms are particularly impacted, with regions like Asia-Pacific and Europe facing significant import duties. This has caused pricing adjustments and supply chain reconfigurations. On the positive side, tariffs encourage local API production, investment in domestic manufacturing facilities, and innovation in cost-efficient formulation development.

The nexletol market research report is one of a series of new reports that provides nexletol market statistics, including nexletol industry global market size, regional shares, competitors with a nexletol market share, detailed nexletol market segments, market trends and opportunities, and any further data you may need to thrive in the nexletol industry. This nexletol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nexletol is a medication that functions by targeting and inhibiting a specific enzyme involved in cholesterol production in the liver. The primary role of Nexletol (generic name: bempedoic acid) is to reduce low-density lipoprotein cholesterol (LDL-C), commonly known as bad cholesterol, in adults with certain cardiovascular conditions.

The main types of Nexletol include the 180 mg dosage and other dosage forms. The 180 mg strength refers to a specific amount of the active ingredient present in each dose. Routes of administration include oral, injectable, and intravenous methods, and the drug is used for various indications such as hyperlipidemia, atherosclerosis, and cardiovascular disease. It is utilized by multiple end users, including hospitals, clinics, and homecare settings.

The nexletol market consists of sales of non-statin lipid-lowering agents, dietary supplements, and cholesterol absorption inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.